Global UAV Announces Share Consolidation

Share consolidation aligns with pending merger but trading remains halted pending approvals.

What the company is saying

Global UAV Technologies Ltd. (CSE:UAV.X, FSE:YAB) is announcing a share consolidation at a ratio of one post-consolidated share for every 1.324206 pre-consolidated shares, effective October 13, 2026. The company emphasizes that this action is required to meet the condition of having no more than 33,000,000 shares outstanding before closing its proposed business combination with Nexus Peptide Sciences Inc. The announcement is framed as a procedural step to satisfy Canadian Securities Exchange (CSE) requirements for a Fundamental Change transaction. Management, led by Director, President, and CEO Ron Schmitz, confirms that all registered shareholders as of the record date will be processed by Endeavor Trust Corporation. The company also notes that the trading symbol UAV.X will remain unchanged, with new CUSIP (379433402) and ISIN (CA3794334027) numbers assigned post-consolidation. The tone is factual, focusing on regulatory compliance and mechanics rather than operational or financial performance.

What the data suggests

The company currently has 43,698,801 shares outstanding, which will be reduced to 33,000,002 shares after the consolidation, subject to rounding. The consolidation ratio is precisely 1.324206 pre-consolidated shares per one post-consolidated share, with any fractional shares rounded up. The share count post-consolidation is designed to meet the CSE's requirement of no more than 33,000,000 shares outstanding prior to the merger with Nexus Peptide Sciences Inc. The announcement does not include financial performance metrics, revenue, or operational updates, focusing solely on share structure and regulatory compliance. Convertible securities will be adjusted proportionately, but no details are provided on the number or type of these instruments. Trading in the company's securities remains halted pending CSE review of the proposed transaction, and completion is still subject to regulatory and customary closing conditions. The data is complete for the share consolidation mechanics but does not address financial health or business fundamentals.

Analysis

The announcement is a factual, procedural update regarding a share consolidation and the status of a pending business combination. The language is neutral and does not attempt to overstate the significance or potential benefits of the actions described. All key claims about the share consolidation are supported by specific numerical data (ratios, share counts, effective date), and the forward-looking statements are limited to standard regulatory caveats about the completion of the transaction. There are no exaggerated claims about future value creation, synergies, or operational improvements. The business combination is described as pending and subject to approval, with no promotional language about its potential impact. No large capital outlay or immediate financial benefit is claimed, and the disclosure is transparent about the conditional nature of the transaction.

Risk flags

• ●Completion of the business combination with Nexus Peptide Sciences Inc. is not guaranteed, as it is subject to CSE approval and other customary closing conditions. If these are not met, the transaction may not proceed.
• ●Trading in Global UAV Technologies Ltd.'s securities remains halted pending regulatory review, which limits liquidity and may delay any potential value realization for shareholders.
• ●The announcement provides no financial or operational performance data, leaving investors without insight into the underlying business fundamentals or the strategic rationale for the merger beyond regulatory compliance.

Bottom line

This announcement is a mechanical step to reduce Global UAV Technologies Ltd.'s outstanding shares from 43,698,801 to 33,000,002, effective October 13, 2026, to meet CSE requirements for a pending merger with Nexus Peptide Sciences Inc. The share consolidation itself does not create value but is necessary for the proposed business combination, which remains subject to regulatory and customary approvals. Trading remains halted, so investors cannot act until the CSE review is complete. The release is transparent about the process but does not provide operational or financial context for the merger. The key takeaway is that progress toward the merger depends entirely on regulatory clearance, and there is no assurance the transaction will close as planned.

Announcement summary

(CSE:UAV.X) (FSE:YAB) Global UAV Technologies Ltd. has announced its intention to consolidate its common shares on the basis of one post-consolidated share for each 1.324206 pre-consolidated shares issued and outstanding. The consolidation will become effective at the opening of the market on October 13, 2026. The company's trading symbol "UAV.X" will remain unchanged. The new CUSIP number for the post-consolidation shares will be 379433402 and the new ISIN number will be CA3794334027. Currently, there are 43,698,801 shares issued and outstanding. Upon the consolidation becoming effective, there will be 33,000,002 shares issued and outstanding, subject to adjustments for rounding. Any fractional shares resulting from the exchange will be rounded up to the nearest whole share. The exercise or conversion price and the number of shares issuable with respect to any of the company's outstanding convertible securities will be proportionately adjusted in connection with the consolidation. There is no maximum number of authorized shares. The company previously entered into an amalgamation agreement with Nexus Peptide Sciences Inc. to complete a business combination transaction constituting a Fundamental Change under the policies of the Canadian Securities Exchange (CSE). The consolidation is being completed to satisfy the requirement that the company have no more than 33,000,000 shares issued and outstanding immediately prior to closing. Completion of the transaction remains subject to a number of conditions, including CSE approval and the satisfaction of other customary closing conditions. There can be no assurance that the transaction will be completed as proposed or at all. Trading in the company's securities remains halted in accordance with the policies of the CSE pending completion of the review process in respect of the proposed transaction. Endeavor Trust Corporation has confirmed that all shares held by registered shareholders as of the record date on October 13, 2026, will be processed. Ron Schmitz is the Director, President and CEO of Global UAV Technologies Ltd.

Disagree with this article?